Immune adjuvant is an artificial PAMP for potentiating various immune responses.
we introduce the pathways by which CTL and NK cells are driven through mDC maturation in response to adjuvants.
Microbial pattern molecules (PAMP, pathogen-associated molecular patterns) are agonists of pattern-recognition receptors, a representative of which is Toll-like receptor.
Adjuvants are non-infectious artificial PAMP, typically administered with the target antigen (Ag) in order to enhance the host immune response (1) . However, the mechanism by which these reagents enhance immunity had not clearly been understood, until the recent progress on elucidation of the ligand properties of Toll-like receptors (TLRs) and TLR-mediated DC maturation (2) . The accumulated evidence on TLR-dependent DC maturation has solidified the current understanding that DC TLRs confer direction of effector driving on the DCs that present antigens. Now, we hold that Ags determine the object toward which immune cells are proliferated whereas adjuvant determines what effectors will be selected for immunological output (1) . The fundamental concepts of the immune system should be re-evaluated through the understanding of TLR-mediated DC immune responses, which will also revolutionize the concepts related to vaccination.
In myeloid DCs (mDCs), a representative Ag-presenting cells, the two major arms of the innate immune signaling pathway, the MyD88 and TICAM-1 (TRIF) pathways, have been identified through the investigation of TLR signaling (2) There is almost no information concerning the molecular mechanisms driving these effector cells in mDCs. Each DC subset seems to correspond to a specific effector, although the selection mechanism by which DCs induce various effectors is not clear in most instances. However, it is known from mouse models that splenic CD8+ DCs induce Treg For future studies, it is necessary to determine the potential of peptide-conjugating materials including Ags and inflammation-inducing reagents. A number of reports have suggested that adjuvants can greatly increase the efficiency rate of treatment, although there are no criteria to fairly evaluate the function of adjuvants in vaccine recipients or patients.
The method for stimulating DCs needs to be carefully selected as systemic administration of inflammation-inducing material can also lead to the acceleration or exacerbation of infection at the same time. In this case, the route and molecule that selectively raises the degree of DC maturation without severe malicious inflammation should be clarified. The design of DC maturation can be manipulated without helping flare inflammation. In the future, we hope that through continued research, patients will have access to convenient and highly effective prophylactic immunotherapy.
